| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian-Hai Guo, Shao-Xing Liu, Song Gao, Fu-Xin Kou, Xin Zhang, Di Wu, Xiao-Ting Li, Hui Chen, Xiao-Dong Wang, Peng Liu, Peng-Jun Zhang, Hai-Feng Xu, Guang Cao, Lin-Zhong Zhu, Ren-Jie Yang and Xu Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Sanofi |
|
|
| Corresponding Author |
Xu Zhu, MD, Chief Doctor, Professor, Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com |
| Key Words |
Hepatocellular carcinoma; Advanced; Hepatic arterial infusion chemotherapy; Transarterial chemoembolization; Prognosis; Efficacy |
| Core Tip |
This randomized controlled trial showed that the addition of oral S-1 (a composite preparation of a 5-fluorouracil prodrug) to transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin did not lengthen the survival times of patients with advanced hepatocellular carcinoma (HCC) complicating portal vein invasion or extrahepatic metastasis, although it did lead appear to have moderately better anti-tumor activity. TACE combined with HAIC was an effective and safe treatment for patients with advanced HCC with portal vein invasion or extrahepatic metastasis. |
| Publish Date |
2020-07-21 13:23 |
| Citation |
Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i27/3975.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i27.3975 |
